News and Comments


Prohost Biotech - Wednesday, September 26, 2012

CSHL Scientists Use Cancer Drugs to Reverse Alzheimer's-Like Memory Loss

in 2 Animal Models

EGFR inhibitors used to fight cancer show surprising efficacy in fly, mouse models of beta amyloid-associated memory loss.

Cold Spring Harbor, NY (PRWEB) September 24, 2012:  

A team of neuroscientists and chemists from the U.S. and China today publish research suggesting that a class of currently used anti-cancer drugs as well as several previously untested synthetic compounds show effectiveness in reversing memory loss in two animal models of Alzheimer's' disease.

CSHL Professor Yi Zhong, Ph.D., who led the research conducted in fruit flies and mice, says he and his colleagues were surprised with their results, which, he stressed, used two independent experimental approaches "the results of which clearly converged."

Specifically, the research converged on what Zhong's team suggests is a "preferred target" for treating memory loss associated with the amyloid-beta (Aβ) plaques seen in advanced Alzheimer's patients. That target is the epidermal growth factor receptor, often called by its acronym, EGFR.

Overexpression of the EGFR is a characteristic feature of certain cancers, notably a subset of lung cancers. Two targeted treatments, erlotinib (Tarceva) and gefitinib (Iressa), can dramatically, albeit transiently, reverse EGFR-positive cancers, by blocking the EGFR receptor and thus preventing its activation.

The newly published research by Zhong's team suggests that the signaling within cells that is induced by EGFR activation also plays a role in the pathology – still poorly understood – involved in Aβ-associated memory loss seen in Alzheimer's patients.

Zhong and colleagues previously had studied Aβ-associated memory loss in fruit flies with brain cells expressing the Aβ-42 peptide (a specific version of the protein, composed of 42 amino acids, seen in Alzheimer's plaques). These fruit flies are regarded as models of the illness in part because the Aβ-42 they manifest is encoded by a human gene, inserted in their genome. In behavioral experiments, such flies have been shown to suffer memory deficiencies analogous to those seen in human Alzheimer's.

Enhanced activation of EGFR exacerbates memory loss in flies

In the current round of experiments, Zhong's team demonstrated that enhanced activation of EGFRs in brain cells exacerbated memory loss in the Aβ-42 fruit fly model of Alzheimer's disease. This led them to dose 3-day-old flies of the same type with the two anti-cancer EGFR inhibitors over a week's time, which was shown in behavioral tests on day 11 to prevent memory loss. The results were then confirmed in mouse models of Alzheimer's, also based on the human Aβ-42 gene.

This was remarkable, but even more so, says Zhong, because of a parallel but independent experimental process that also suggested EGFR as a drug target for Alzheimer's. This parallel process consisted of screening, by Zhong's collaborators in China, of some 2,000 synthetic compounds for activity against Aβ-induced memory loss in model fruit flies. Of these, 45 compounds showed positive results in fruit flies after two months of dosing. Nine of these were selected for testing in mouse models, of which four showed positive results after two months.

"We were amazed to find that three of these compounds – designated JKF-006, JKF-011 and JKF-027 – not only showed effective results in rescuing memory loss in the mice, but also, in test-tube-based experiments, prevented Aβ-42 from activating human EGFR," Zhong reports.

Blocking EGFR signaling appeared to prevent memory loss

Importantly, a precise mechanism could not be conclusively demonstrated from this and related experiments. But the available evidence leads the scientists to propose in a paper appearing online today in Proceedings of the National Academy of Sciences, that reversal of memory loss occurs when clumps of beta-amyloid proteins are either prevented directly from "docking" with the human EGF receptor, or prevent phosphate groups from attaching to the receptor, a process called phosphorylation. Both hypothesized processes would prevent the initiation of the EGFR intracellular signaling cascade.

Zhong and colleagues note the uncertainty of Alzheimer's pathology. Memory loss stemming from Aβ-induced activation of EGFR "may reflect the acute toxic effects of Aβ, which might be independent of synaptic and neuronal degeneration," they note. To gain more insight, the team tested drug treatment of middle-aged mice (8 months old) with advanced memory loss during an 18-day period – some six weeks shorter than the dosing period initially shown to be effective.

"Eighteen days – the shortest dosing period we tested – was sufficient to reverse loss in these mice, although we should note that these animals had few morphological changes in the brain despite their severe memory loss when treatment began," Zhong says.

Because of the positive results they obtained in reversing memory loss in animal models, the team suggests additional testing with EGFR inhibitors be conducted, as well as testing of "behaviorally screened chemicals in treatments of Alzheimer's patients."

"Epidermal growth factor receptor is a preferred target for treating Aβ-induced memory loss" appears online ahead of print September 24 in Proceedings of the National Academy of Sciences. the authors are: Lei Wang, Hsueh-cheng Chiang, Wenjuan Wu, Bin Liang, Zuolei Xie, Xingsheng Yao, Weiwei Ma, Shuwen Du and Yi Zhong.

This work was supported by grants from Cold Spring Harbor Laboratory, Dart Neuroscience, the Ministry of Science and Technology of China, and the Tsinghua-Yue-Yuen Medical Sciences Fund.

About Cold Spring Harbor Laboratory

Founded in 1890, Cold Spring Harbor Laboratory (CSHL) has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. CSHL is ranked number one in the world by Thomson Reuters for impact of its research in molecular biology and genetics. The Laboratory has been home to eight Nobel Prize winners. Today, CSHL's multidisciplinary scientific community is more than 360 scientists strong and its Meetings & Courses program hosts more than 12,500 scientists from around the world each year to its Long Island campus and its China center. Tens of thousands more benefit from the research, reviews, and ideas published in journals and books distributed internationally by CSHL Press. The Laboratory's education arm also includes a graduate school and programs for undergraduates as well as middle and high school students and teachers. CSHL is a private, not-for-profit institution on the north shore of Long Island. For more information, visit

Post has no comments.
Post a Comment

Captcha Image

Trackback Link
Post has no trackbacks.

Recent Postings



PTC Therapeutics (PTCT) VANDA (VNDA) Spike Therapeutics (ONCE) NANTKWEST (NK) SUNESIS PHARMACEUTICALS (SNSS) INNOVIVA (INVA) Valeant Pharmaceuticals International (VRX) GlaxoSmithKline (GSK) CompuGen (CGEN) Ridaforolimus Intrexon (XON) Multiple Myeloma ZALTRAP™ Merck (MRK) Abbott Laboratories (ABT) Human Longevity (HLI) Genentech Trastuzumab-DM1 AGOS (ARGS) Intercept (ICPT) Alder Biopharmaceuticals (ALDR) NEKTAR (NKTR)) SERES THERAPEUTICS (MCRB) Vitae Pharmaceuticals (VTAE) Seattle Genetics (SGEN) ARGOS (ARGS) Telaprevir KITE (KITE) Idenix (IDIX) Roche (RHHBY) Cytokinetics (CYTK) Zerenex Ionis (IONS) Sarepta (SRPT) ACADIA (ACAD) Anacor (ANAC) Revlimid (lenolidamide) Alnylam (ALNY) ABBVIE (ABBV) Sangamo (SGMO) KERYX (KERX) BIOMARIN (BMRN) Theravance (THRX) ARCA (ABIO) OSI (OSIP) Auspex (ASPX) Biogen Idec (BIIB) GUARDIAN HEALTH Rapamune Dynavax (DVAX) Bristol-Myers Squibb (BMY) Biocryst (BCRX) TOKAI (TKAOI) Prosensa (RNA) Intermune (ITMN) Ariad (ARIA) Aimmune Therapeutics (AIMT) Elan (ELN) Prolor Biotech (PBTH) Micromet (MITI) Sequenom (SQNM) Jazz Pharmaceuticals (JAZZ) JUNO (JUNO) Human Genome Sciences (HGSI) Sanofi (SNA) C4 Therapeutics Roche (ROCHE) Amgen (AMGN) Inovio (INO) galapagos (GLPG) Mirati Therapeutics (MRTX) Endometrial Cancer Tysabri Galena (GALE) Editas (EDIT) Array Pharmaceuticals (ARRY) ImmunoGen (IMGN) Dendreon (DNDN) AERIE PHARMACEUTICALS Herceptin Pluristem (PSTI) Sanofi-Aventis (SAN) Exelixis (EXEL) Illumina (ILMN) Theravance Bio Pharma (TBPH) ADVENTRIX (ANX) SYNTA (SNTA) REGULUS (RGLS) ISIS (ISIS) IDERA (IDRA) Sanofi (SNY) Agenus (AGEN) Regeneron (REGN) Anadys (ANDS) RenenxBio (RGNX) Xoma (XOMA) Velcade (bortezomib) Benlysta (belimumab) Agenus (AGEN Incyte (INCY) Gilead (GILD) Global Cell Therapeutics (GBT) HALOZYME (HALO) Vertex (VRTX) Onyx (ONXX) Ziofpharm (ZIOP)